drugset / Trial / NCT04747002
Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.
Phase 2
Unknown
100 enrolled
Osaka University
Japan Agency for Medical Research and Development · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is an investigator-initiated clinical trial (Phase II) using DSP-7888 for acute myeloid leukemia patients with 1st hematological complete remission (CR). DSP-7888 is a novel cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize Wilms Tumor Gene 1 (WT1) peptides.
Timeline
- Start
- 2020-06-12
- Primary completion
- 2024-03
- Completion
- 2024-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ombipepimut-S | Vaccine | — | — |